This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08960/identifier/wikipedia/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08960/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08960
rdf:type
n3:Drug
n3:description
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
n3:generalReferences
# Adams DJ, Bevan S, Terrar DA: Modes of hexamethonium action on acetylcholine receptor channels in frog skeletal muscle. Br J Pharmacol. 1991 Jan;102(1):135-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1710523
n3:group
experimental
owl:sameAs
n7:DB08960
dcterms:title
Hexamethonium
adms:identifier
n9:Hexamethonium n10:DB08960
n3:synonym
N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium
n3:salt
n3:synthesisReference
U.S. Patent 2,641,610.
n3:IUPAC-Name
n4:271B6030-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6036-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6035-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6032-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6033-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6034-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B602E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B602F-363D-11E5-9242-09173F13E4C5 n4:271B602C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B602D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B603C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B603D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6037-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6038-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B603A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6039-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B603B-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
60-26-4
n3:Bioavailability
n4:271B6040-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6042-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6043-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6044-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B603F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B603E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6041-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6031-363D-11E5-9242-09173F13E4C5